

## PROGRESS REPORT PUBLICATION LIST

### RESEARCH EDUCATION COMPONENT (REC)

**June 2015 – September 2019: 91 publications including 52 first or senior author publications**

**Note:** 4 co-authored manuscripts between scholars

- #20 and #50 collaboration between Ross and Reveles
- #52 and #71 collaboration between Reveles and Orr
- #46 and #83 collaboration between Reveles and Lee
- #70 and #91 collaboration between Orr and Nie

### PHASE 2 SCHOLARS

**Corinna Ross, PhD**

#### Phase 1 Publications (6/15 to 4/17)

1. **Ross C**, Salmon A, Strong R, Fernandez E, Javors M, Richardson A, Tardif S. Metabolic consequences of long-term rapamycin exposure on common marmoset monkeys (*Callithrix jacchus*). *Aging* (Albany NY). 2015;7(11):964-73. Epub 2015/11/17. doi: 10.18632/aging.100843. PubMed PMID: 26568298; PMCID: PMC4694066.
2. Lelegren M, Liu Y, **Ross C**, Tardif S, Salmon AB. Pharmaceutical inhibition of mTOR in the common marmoset: effect of rapamycin on regulators of proteostasis in a non-human primate. *Pathobiol Aging Age Relat Dis*. 2016;6:31793. Epub 2016/06/28. doi: 10.3402/pba.v6.31793. PubMed PMID: 27341957; PMCID: PMC4920937.
3. Phillips KA, **Ross CN**, Spross J, Cheng CJ, Izquierdo A, Biju KC, Chen C, Li S, Tardif SD. Behavioral phenotypes associated with MPTP induction of partial lesions in common marmosets (*Callithrix jacchus*). *Behav Brain Res*. 2017;325(Pt A):51-62. Epub 2017/02/22. doi: 10.1016/j.bbr.2017.02.010. PubMed PMID: 28219749; PMCID: PMC5410665.
4. **Ross CN**. Now, where are those matches at the end of this tunnel? *Future healthcare journal*. 2017;4(2):151-2. Epub 2017/06/01. doi: 10.7861/futurehosp.4-2-151a. PubMed PMID: 31098459; PMCID: PMC6502627.
5. **Ross CN**, Austad S, Brasky K, Brown CJ, Forney LJ, Gelfond JA, Lanford R, Richardson A, Tardif SD. The development of a specific pathogen free (SPF) barrier colony of marmosets (*Callithrix jacchus*) for aging research. *Aging* (Albany NY). 2017;9(12):2544-58. Epub 2017/12/12. doi: 10.18632/aging.101340. PubMed PMID: 29227963; PMCID: PMC5764392.
6. Williams L, **Ross CN**. Behavioral management of Neotropical Primates: Aotus, Callithrix & Saimiri. In: Schapiro S, editor. *Handbook of Primate Behavioral Management*: CRC Press; 2017.

#### Phase 2 Publications (5/17 to present)

7. Bentley RA, **Ross CN**, O'Brien MJ. Obesity, Metabolism, and Aging: A Multiscalar Approach. *Progress in molecular biology and translational science*. 2018;155:25-42. Epub 2018/04/15. doi: 10.1016/bs.pmbts.2017.11.016. PubMed PMID: 29653680.
8. Riesche L, Tardif SD, **Ross CN**, deMartelly VA, Ziegler T, Rutherford JN. The common marmoset monkey: avenues for exploring the prenatal, placental, and postnatal mechanisms in developmental programming of pediatric obesity. *American journal of physiology Regulatory, integrative and comparative physiology*. 2018;314(5):R684-r92. Epub 2018/02/08. doi: 10.1152/ajpregu.00164.2017. PubMed PMID: 29412686; PMCID: PMC6008109.
9. **Ross CN**. Marmosets in Aging Research. In: Marini RP, Wachtman LM, Tardif SD, Mansfield K, Fox JG, editors. *The Common Marmoset in Captivity and Biomedical Research*: Elsevier/Academic Press; 2018. p. 355-76.
10. **Ross CN**, Salmon A. Aging research using the common marmoset: Focus on aging interventions. *Nutr Healthy Aging*. 2018;Pre-press(Pre-press):1-13.

11. Tardif SD, **Ross CN**. Reproduction, growth and development. In: Marini RP, Wachtman LM, Tardif SD, Mansfield K, Fox JG, editors. *The Common Marmoset in Captivity and Biomedical Research*: Elsevier/Academic Press; 2018. p. 119-32.
12. Brown CJ, Mtui D, Oswald BP, Van Leuven JT, Vallender EJ, Schultz-Darken N, **Ross CN**, Tardif SD, Austad SN, Forney LJ. Comparative genomics of Bifidobacterium species isolated from marmosets and humans. *American journal of primatology*. 2019:e983. Epub 2019/05/08. doi: 10.1002/ajp.22983. PubMed PMID: 31062394.
13. Fernandez E, **Ross C**, Liang H, Javors M, Tardif S, Salmon AB. Evaluation of the pharmacokinetics of metformin and acarbose in the common marmoset. *Pathobiol Aging Age Relat Dis*. 2019;9(1):1657756. Epub 2019/09/10. doi: 10.1080/20010001.2019.1657756. PubMed PMID: 31497263; PMCID: PMC6719263.
14. Hoffman JM, **Ross C**, Tran V, Promislow DEL, Tardif S, Jones DP. The metabolome as a biomarker of mortality risk in the common marmoset. *American journal of primatology*. 2019;81(2):e22944. Epub 2018/12/27. doi: 10.1002/ajp.22944. PubMed PMID: 30585652; PMCID: PMC6599709.
15. Lee HJ, Gonzalez O, Dick EJ, Donati A, Feliers D, Choudhury GG, **Ross C**, Venkatachalam M, Tardif SD, Kasinath BS. Marmoset as a Model to Study Kidney Changes Associated With Aging. *The journals of gerontology Series A, Biological sciences and medical sciences*. 2019;74(3):315-24. Epub 2018/10/16. doi: 10.1093/gerona/gly237. PubMed PMID: 30321310; PMCID: PMC6376089.
16. **Ross C**, Aging in Chapter 4 Research Applications, National Academies of Sciences E, Medicine. Care, Use, and Welfare of Marmosets as Animal Models for Gene Editing-Based Biomedical Research: Proceedings of a Workshop. Johnson AF, Anestidou L, editors. Washington, DC: The National Academies Press; 2019. 100 p.
17. Parambeth JC, **Ross CN**, Miller AD, Austad SN, Lidbury JA, Suchodolski JS, Steiner JM. Serum Cobalamin and Folate Concentrations in Common Marmosets (*Callithrix jacchus*) with Chronic Lymphocytic Enteritis. *Comparative medicine*. 2019;69(2):135-43. Epub 2019/03/25. doi: 10.30802/aalas-cm-18-000045. PubMed PMID: 30902119; PMCID: PMC6464084.
18. Phillips KA, Watson CM, Bearman A, Knippenberg AR, Adams J, **Ross C**, Tardif SD. Age-related changes in myelin of axons of the corpus callosum and cognitive decline in common marmosets. *American journal of primatology*. 2019;81(2):e22949. Epub 2019/01/09. doi: 10.1002/ajp.22949. PubMed PMID: 30620098; PMCID: PMC6685070.
19. Power ML, Adams J, Solonika K, Colman RJ, **Ross C**, Tardif SD. Diet, digestion and energy intake in captive common marmosets (*Callithrix jacchus*): research and management implications. *Scientific reports*. 2019;9(1):12134. Epub 2019/08/23. doi: 10.1038/s41598-019-48643-x. PubMed PMID: 31431664; PMCID: PMC6702194.
20. Reveles KR, Patel S, Forney L, **Ross CN**. Age-related changes in the marmoset gut microbiome. *American journal of primatology*. 2019;81(2):e22960. Epub 2019/02/26. doi: 10.1002/ajp.22960. PubMed PMID: 30802990; PMCID: PMC6414241.
21. **Ross CN**, Adams J, Gonzalez O, Dick E, Giavedoni L, Hodara VL, Phillips K, Rigodanzo AD, Kasinath B, Tardif SD. Cross-sectional comparison of health-span phenotypes in young versus geriatric marmosets. *American journal of primatology*. 2019;81(2):e22952. Epub 2019/01/22. doi: 10.1002/ajp.22952. PubMed PMID: 30664265.
22. Sills AM, Artavia JM, DeRosa BD, **Ross CN**, Salmon AB. Long-term treatment with the mTOR inhibitor rapamycin has minor effect on clinical laboratory markers in middle-aged marmosets. *American journal of primatology*. 2019;81(2):e22927. Epub 2018/10/13. doi: 10.1002/ajp.22927. PubMed PMID: 30311681; PMCID: PMC6415526.
23. Murphy AM, **Ross CN**, Bliss-Moreau E. Non-invasive cardiac psychophysiology as a tool for translational science with marmosets. *American journal of primatology*. In press.

## Kelly Reveles, PharmD, PhD

### Phase 1 Publications (6/15 to 4/17)

24. Aitken SL, **Reveles KR**. Response to "Effect of geographic region and seasonality on Clostridium difficile incidence and hospital mortality". American journal of infection control. 2015;43(12):1379. Epub 2015/09/01. doi: 10.1016/j.ajic.2015.07.031. PubMed PMID: 26320700.
25. **Reveles KR**, Mortensen EM, Attridge RT, Frei CR. Comparative-effectiveness of vancomycin and linezolid as part of guideline-recommended empiric therapy for healthcare-associated pneumonia. BMC Res Notes. 2015;8:450. Epub 2015/09/19. doi: 10.1186/s13104-015-1396-1. PubMed PMID: 26382940; PMCID: PMC4573683.
26. Teshome BF, Lee GC, **Reveles KR**, Attridge RT, Koeller J, Wang CP, Mortensen EM, Frei CR. Application of a methicillin-resistant Staphylococcus aureus risk score for community-onset pneumonia patients and outcomes with initial treatment. BMC infectious diseases. 2015;15:380. Epub 2015/09/20. doi: 10.1186/s12879-015-1119-1. PubMed PMID: 26385225; PMCID: PMC4575496.
27. Argamany JR, Delgado A, **Reveles KR**. Clostridium difficile infection health disparities by race among hospitalized adults in the United States, 2001 to 2010. BMC infectious diseases. 2016;16(1):454. Epub 2016/08/29. doi: 10.1186/s12879-016-1788-4. PubMed PMID: 27568176; PMCID: PMC5002147.
28. Argamany JR, **Reveles KR**, Duhon B. Synthetic cannabinoid hyperemesis resulting in rhabdomyolysis and acute renal failure. Am J Emerg Med. 2016;34(4):765 e1-2. Epub 2015/10/01. doi: 10.1016/j.ajem.2015.08.051. PubMed PMID: 26422191.
29. Arizpe A, **Reveles KR**, Aitken SL. Regional variation in antibiotic prescribing among medicare part D enrollees, 2013. BMC infectious diseases. 2016;16(1):744. Epub 2016/12/13. doi: 10.1186/s12879-016-2091-0. PubMed PMID: 27938336; PMCID: PMC5148872.
30. Arizpe A, **Reveles KR**, Patel SD, Aitken SL. Updates in the Management of Cephalosporin-Resistant Gram-Negative Bacteria. Curr Infect Dis Rep. 2016;18(12):39. Epub 2016/10/16. doi: 10.1007/s11908-016-0552-7. PubMed PMID: 27743202.
31. Duhon BM, Hand EO, Howell CK, **Reveles KR**. Retrospective cohort study evaluating the incidence of diabetic foot infections among hospitalized adults with diabetes in the United States from 1996-2010. American journal of infection control. 2016;44(2):199-202. Epub 2015/11/07. doi: 10.1016/j.ajic.2015.09.012. PubMed PMID: 26541067.
32. Pechal A, Lin K, Allen S, **Reveles K**. National age group trends in Clostridium difficile infection incidence and health outcomes in United States Community Hospitals. BMC infectious diseases. 2016;16(1):682. Epub 2016/11/20. doi: 10.1186/s12879-016-2027-8. PubMed PMID: 27855653; PMCID: PMC5114740.
33. **Reveles KR**, Duhon BM, Moore RJ, Hand EO, Howell CK. Epidemiology of Methicillin-Resistant Staphylococcus aureus Diabetic Foot Infections in a Large Academic Hospital: Implications for Antimicrobial Stewardship. PloS one. 2016;11(8):e0161658. Epub 2016/08/25. doi: 10.1371/journal.pone.0161658. PubMed PMID: 27556897; PMCID: PMC4996514.

### Phase 2 Publications (5/17 to present)

34. Britt RS, Evoy KE, Lee GC, **Reveles KR**, Sorensen KM, Jones X, Bollinger M, Frei CR. Early Use of Ceftaroline Fosamil in the United States Veterans Health Care System. Drugs. 2017;77(12):1345-51. Epub 2017/07/01. doi: 10.1007/s40265-017-0785-2. PubMed PMID: 28664412; PMCID: PMC5553123.
35. Delgado A, Reveles IA, Cabello FT, **Reveles KR**. Poorer outcomes among cancer patients diagnosed with Clostridium difficile infections in United States community hospitals. BMC infectious diseases. 2017;17(1):448. Epub 2017/06/25. doi: 10.1186/s12879-017-2553-z. PubMed PMID: 28645266; PMCID: PMC5481960.
36. Howell CK, **Reveles KR**, Knodel LC, Pattyn NR, Frei CR. Know your medicine: A novel student-led community service learning program. Curr Pharm Teach Learn. 2017;9(3):353-9. Epub 2017/12/14. doi: 10.1016/j.cptl.2017.01.006. PubMed PMID: 29233271.
37. Reveles IA, **Reveles KR**, Frei BL, Frei CR, Koeller JM. Cost of squamous cell cancer of the head and neck. Am J Pharm Benefits. 2017;9(3):89-94. Epub May 2017.

38. **Reveles KR**, Backo JL, Corvino FA, Zivkovic M, Broderick KC. Fidaxomicin versus Vancomycin as a First-Line Treatment for Clostridium difficile-Associated Diarrhea in Specific Patient Populations: A Pharmacoeconomic Evaluation. *Pharmacotherapy*. 2017;37(12):1489-97. Epub 2017/10/19. doi: 10.1002/phar.2049. PubMed PMID: 29044643.
39. **Reveles KR**, Lawson KA, Mortensen EM, Pugh MJV, Koeller JM, Argamany JR, Frei CR. National epidemiology of initial and recurrent Clostridium difficile infection in the Veterans Health Administration from 2003 to 2014. *PloS one*. 2017;12(12):e0189227. Epub 2017/12/08. doi: 10.1371/journal.pone.0189227. PubMed PMID: 29216276; PMCID: PMC5720754.
40. Bustillos H, Leer K, Kitten A, **Reveles KR**. A cross-sectional study of national outpatient gastric acid suppressant prescribing in the United States between 2009 and 2015. *PloS one*. 2018;13(11):e0208461. Epub 2018/12/01. doi: 10.1371/journal.pone.0208461. PubMed PMID: 30500865; PMCID: PMC6267968.
41. Evoy KE, Hill LG, Groff L, Mazin L, Carlson CC, **Reveles KR**. Naloxone Accessibility Without a Prescriber Encounter Under Standing Orders at Community Pharmacy Chains in Texas. *Jama*. 2018;320(18):1934-7. Epub 2018/11/14. doi: 10.1001/jama.2018.15892. PubMed PMID: 30422186; PMCID: PMC6248133.
42. **Reveles KR**, Mortensen EM, Koeller JM, Lawson KA, Pugh MJV, Rumbellow SA, Argamany JR, Frei CR. Derivation and Validation of a Clostridium difficile Infection Recurrence Prediction Rule in a National Cohort of Veterans. *Pharmacotherapy*. 2018;38(3):349-56. Epub 2018/02/03. doi: 10.1002/phar.2088. PubMed PMID: 29393522; PMCID: PMC5867250.
43. **Reveles KR**, Pugh MJV, Lawson KA, Mortensen EM, Koeller JM, Argamany JR, Frei CR. Shift to community-onset Clostridium difficile infection in the national Veterans Health Administration, 2003-2014. *American journal of infection control*. 2018;46(4):431-5. Epub 2017/11/12. doi: 10.1016/j.ajic.2017.09.020. PubMed PMID: 29126751.
44. **Reveles KR**, Ryan CN, Chan L, Cosimi RA, Haynes WL. Proton pump inhibitor use associated with changes in gut microbiota composition. *Gut*. 2018;67(7):1369-70. Epub 2017/10/11. doi: 10.1136/gutjnl-2017-315306. PubMed PMID: 28993417; PMCID: PMC6031263.
45. Whitaker A, Cosimi RA, **Reveles KR**, Evoy KE. Bezlotoxumab: a novel drug for reduction of recurrent Clostridium difficile infections. *Infect Dis Clin Pract*. 2018;26(2):60-5. Epub March 2018. doi: 10.1097/IPC.0000000000000571.
46. Argamany JR, Lee GC, Duhon BD, Zeidan AR, Young EH, **Reveles KR**. A possible association between statin use and improved Clostridioides difficile infection mortality in veterans. *PloS one*. 2019;14(5):e0217423. Epub 2019/05/29. doi: 10.1371/journal.pone.0217423. PubMed PMID: 31136602; PMCID: PMC6538245.
47. Hill LG, Evoy KE, **Reveles KR**. Pharmacists are missing an opportunity to save lives and advance the profession by embracing opioid harm reduction. *Journal of the American Pharmacists Association : JAPhA*. 2019. Epub 2019/08/14. doi: 10.1016/j.japh.2019.06.019. PubMed PMID: 31402146.
48. Kitten AK, Kamath M, Ryan L, **Reveles KR**. National ambulatory care non-insulin antidiabetic medication prescribing trends in the United States from 2009 to 2015. *PloS one*. 2019;14(8):e0221174. Epub 2019/08/15. doi: 10.1371/journal.pone.0221174. PubMed PMID: 31412090; PMCID: PMC6693747.
49. **Reveles KR**, Dotson KM, Gonzales-Luna A, Surati D, Endres BT, Alam MJ, Garey KW. Clostridioides (Formerly Clostridium) difficile Infection During Hospitalization Increases the Likelihood of Nonhome Patient Discharge. *Clinical infectious diseases : an official publication of the Infectious Diseases Society of America*. 2019;68(11):1887-93. Epub 2018/09/12. doi: 10.1093/cid/ciy782. PubMed PMID: 30204878; PMCID: PMC6522682.
50. **Reveles KR**, Patel S, Forney L, Ross CN. Age-related changes in the marmoset gut microbiome. *American journal of primatology*. 2019;81(2):e22960. Epub 2019/02/26. doi: 10.1002/ajp.22960. PubMed PMID: 30802990; PMCID: PMC6414241.
51. Teng C, **Reveles KR**, Obodozie-Ofoegbu OO, Frei CR. Clostridium difficile Infection Risk with Important Antibiotic Classes: An Analysis of the FDA Adverse Event Reporting System. *International journal of medical sciences*. 2019;16(5):630-5. Epub 2019/06/21. doi: 10.7150/ijms.30739. PubMed PMID: 31217729; PMCID: PMC6566741.
52. Orr ME, **Reveles KR**, Yeh C, Young EH, Han X. Can oral health and oral-derived specimens predict progression of dementia? *Oral Dis*. In press.

53. Hill L, **Reveles KR**, Evoy K. State-level approaches to expanding pharmacists' authority to dispense naloxone may impact accessibility. *JAMA Intern Med*. In press.

### **Sukeshi Patel Arora, MD**

#### **Phase 1 Publications (6/15 to 4/17)**

54. Mahalingam D, **Patel S**, Nuovo G, Gill G, Selvaggi G, Coffey M, Nawrocki ST. The combination of intravenous Reolysin and gemcitabine induces reovirus replication and endoplasmic reticular stress in a patient with KRAS-activated pancreatic cancer. *BMC cancer*. 2015;15:513. Epub 2015/07/15. doi: 10.1186/s12885-015-1518-0. PubMed PMID: 26156229; PMCID: PMC4496814.
55. **Patel S**, Hurez V, Nawrocki ST, Goros M, Michalek J, Sarantopoulos J, Curiel T, Mahalingam D. Vorinostat and hydroxychloroquine improve immunity and inhibit autophagy in metastatic colorectal cancer. *Oncotarget*. 2016;7(37):59087-97. Epub 2016/07/28. doi: 10.18632/oncotarget.10824. PubMed PMID: 27463016; PMCID: PMC5312297.
56. Fountzilas C, Stuart S, Hernandez B, Bowhay-Carnes E, Michalek J, Sarantopoulos J, Karnad A, **Patel S**, Weitman S, Mahalingam D. Risks and benefits of phase I liver dysfunction studies: should patients with severe liver dysfunction be included in these trials? *Investigational new drugs*. 2017;35(3):386-91. Epub 2017/01/20. doi: 10.1007/s10637-017-0425-4. PubMed PMID: 28102465.

#### **Phase 2 (5/17 to present)**

57. Fountzilas C, **Patel S**, Mahalingam D. Review: Oncolytic virotherapy, updates and future directions. *Oncotarget*. 2017;8(60):102617-39. Epub 2017/12/20. doi: 10.18632/oncotarget.18309. PubMed PMID: 29254276; PMCID: PMC5731986.
58. Arellano LM, **Arora SP**. Systemic Treatment of Advanced Hepatocellular Carcinoma in Older Adults. *Journal of nature and science*. 2018;4(8). Epub 2018/09/14. PubMed PMID: 30211314; PMCID: PMC6130815.
59. **Arora SP**, Ketchum NS, Michalek J, Gelfond J, Mahalingam D. Left Versus Right: Does Location Matter for Refractory Metastatic Colorectal Cancer Patients in Phase 1 Clinical Trials? *Journal of gastrointestinal cancer*. 2018;49(3):283-7. Epub 2017/04/23. doi: 10.1007/s12029-017-9948-3. PubMed PMID: 28432610.
60. **Arora SP**, Mahalingam D. Immunotherapy in colorectal cancer: for the select few or all? *Journal of gastrointestinal oncology*. 2018;9(1):170-9. Epub 2018/03/23. doi: 10.21037/jgo.2017.06.10. PubMed PMID: 29564183; PMCID: PMC5848030.
61. Mahalingam D, Goel S, Aparo S, **Patel Arora S**, Noronha N, Tran H, Chakrabarty R, Selvaggi G, Gutierrez A, Coffey M, Nawrocki ST, Nuovo G, Mita MM. A Phase II Study of Pelareorep (REOLYSIN((R))) in Combination with Gemcitabine for Patients with Advanced Pancreatic Adenocarcinoma. *Cancers*. 2018;10(6). Epub 2018/05/26. doi: 10.3390/cancers10060160. PubMed PMID: 29799479; PMCID: PMC6025223.
62. **Arora SP**, Noonan AM, Vanderwalde N, Williams GR. ASCO gastrointestinal cancers symposium: Perspectives on older adults with gastrointestinal malignancies. *Journal of geriatric oncology*. 2019;10(3):371-3. Epub 2019/03/20. doi: 10.1016/j.jgo.2019.03.003. PubMed PMID: 30885663; PMCID: PMC6535130.
63. Mahalingam D, Peguero J, Cen P, **Arora SP**, Sarantopoulos J, Rowe J, Allgood V, Tubb B, Campos L. A Phase II, Multicenter, Single-Arm Study of Mipsagargin (G-202) as a Second-Line Therapy Following Sorafenib for Adult Patients with Progressive Advanced Hepatocellular Carcinoma. *Cancers*. 2019;11(6). Epub 2019/06/20. doi: 10.3390/cancers11060833. PubMed PMID: 31212948; PMCID: PMC6627768.
64. Patel B, Klazynski B, **Arora SP**. High-Grade Large Cell Neuroendocrine Carcinoma: Case Report and Literature Review. *Journal of gastrointestinal cancer*. 2019. Epub 2019/06/30. doi: 10.1007/s12029-019-00267-0. PubMed PMID: 31254245.
65. Sheikh AR, Hsu T, Subbiah IM, **Arora SP**. Perspectives on Geriatric Oncology Research presented at the 2019 American Society of Clinical Oncology (ASCO) Annual Meeting. *Journal of geriatric oncology*. 2019. Epub 2019/07/22. doi: 10.1016/j.jgo.2019.07.011. PubMed PMID: 31326394.

66. **Arora SP**, Liposits G, Caird S, Dunne RF, Moffat GT, Okonji D, Rodriquenz MG, Dua D, Dotan E. Hepatocellular carcinoma in older adults: A comprehensive review by Young International Society of Geriatric Oncology. *Journal of geriatric oncology*. Accepted, minor revisions.
67. Mahalingam D, Eng K, Fields P, Raber P, Moseley J, Cheetham K, Coffey M, Nuovo G, Kalinski P, Zhang B, **Arora SP**, Fountzilias C. Pembrolizumab in combination with the oncolytic virus pelareorep and chemotherapy in patients with advanced pancreatic adenocarcinoma, a Phase 1b study. *Clin Cancer Res*. Accepted, minor revisions.

### **Miranda Orr, PhD**

#### **Phase 1 Publications (5/17 to 4/19)**

68. McDonnell MG, Skalisky J, Leickly E, **Orr ME**, McPherson S, Roll J, Hill-Kapturczak N, Javors M. Pilot investigation of a phosphatidylethanol-based contingency management intervention targeting alcohol use. *Psychology of addictive behaviors : journal of the Society of Psychologists in Addictive Behaviors*. 2017;31(5):608-13. Epub 2017/07/18. doi: 10.1037/adb0000293. PubMed PMID: 28714726; PMCID: PMC6004316.
69. Musi N, Valentine JM, Sickora KR, Baeuerle E, Thompson CS, Shen Q, **Orr ME**. Tau protein aggregation is associated with cellular senescence in the brain. *Aging Cell*. 2018;17(6):e12840. Epub 2018/08/21. doi: 10.1111/ace1.12840. PubMed PMID: 30126037; PMCID: PMC6260915.

#### **Phase 2 Publications (5/19 to present)**

70. Liang H, Nie J, Van Skike CE, Valentine JM, **Orr ME**. Mammalian Target of Rapamycin at the Crossroad Between Alzheimer's Disease and Diabetes. *Advances in experimental medicine and biology*. 2019;1128:185-225. Epub 2019/05/08. doi: 10.1007/978-981-13-3540-2\_10. PubMed PMID: 31062331.
71. **Orr ME**, Reveles KR, Yeh C, Young EH, Han X. Can oral health and oral-derived specimens predict progression of dementia? *Oral Dis*. In press.

### **Lisa Kilpela, PhD, Clinical Psychology**

#### **Phase 1 Publications (5/17 to 4/19)**

72. Becker CB, Verzijl CL, **Kilpela LS**, Wilfred SA, Stewart T. Body image in adult women: Associations with health behaviors, quality of life, and functional impairment. *J Health Psychol*. 2017;24(11):1536-47. Epub 2017/08/16. doi: 10.1177/1359105317710815. PubMed PMID: 28810463.
73. **Kilpela LS**, Schaumberg KE, Hopkins LB, Becker CB. Mechanisms of action during a dissonance-based intervention through 14-month follow-up: The roles of body shame and body surveillance. *Body Image*. 2017;23:171-5. Epub 2017/10/22. doi: 10.1016/j.bodyim.2017.10.003. PubMed PMID: 29055237; PMCID: PMC5714679.
74. Stewart TM, Pollard T, Hildebrandt T, Beyl R, Wesley N, **Kilpela LS**, Becker CB. The Female Athlete Body (FAB) study: Rationale, design, and baseline characteristics. *Contemp Clin Trials*. 2017;60:63-71. Epub 2017/06/15. doi: 10.1016/j.cct.2017.06.005. PubMed PMID: 28611008; PMCID: PMC5546607.
75. Kanzler KE, Pugh JA, McGeary DD, Hale WJ, Mathias CW, **Kilpela LS**, Karns-Wright TE, Robinson PJ, Dixon SA, Bryan CJ, Moring JC, McCracken LM. Mitigating the Effect of Pain Severity on Activity and Disability in Patients with Chronic Pain: The Crucial Context of Acceptance. *Pain Med*. 2018. Epub 2018/12/28. doi: 10.1093/pm/pny197. PubMed PMID: 30590737; PMCID: PMC6686120.

#### **Phase 2 Publications (5/19 to present)**

76. Stewart TM, Pollard T, Hildebrandt T, Wesley NY, **Kilpela LS**, Becker CB. The Female Athlete Body project study: 18-month outcomes in eating disorder symptoms and risk factors. *Int J Eat Disord*. 2019. Epub 2019/07/28. doi: 10.1002/eat.23145. PubMed PMID: 31350934.
77. **Kilpela LS**, Gomez F, Becker CB. Tailoring treatments to middle-aged and older adults. In: Tortolani IC, A. Goldschmidt, Grange DL, editors. *Adapting Evidence-Based Treatments for Eating Disorders for Novel Populations and Settings: A Practical Guide*. UK: Taylor & Francis; In press.

78. **Kilpela LS**, Verzijl CL, Becker CB. Body image in older women: A mediator of BMI and wellness behaviors J Women Aging. In press.
79. **Kilpela LS**, Calogero R, Wilfred SA, Verzijl C, Hale WJ, Becker CB. Self-objectification and eating disorder pathology in an ethnically diverse sample of adult women: Cross-sectional and longitudinal associations. J Eat Disord. In press.

## PHASE 1 SCHOLARS

### Grace Lee, PharmD, PhD

#### Phase 1 Publications (1/18 to present)

80. Kulengowski B, Rutter WC, Campion JJ, **Lee GC**, Feola DJ, Burgess DS. Effect of increasing meropenem MIC on the killing activity of meropenem in combination with amikacin or polymyxin B against MBL- and KPC-producing *Enterobacter cloacae*. *Diagn Microbiol Infect Dis*. 2018;92(3):262-6. Epub 2018/08/14. doi: 10.1016/j.diagmicrobio.2018.06.013. PubMed PMID: 30098852.
81. Shurko JF, Galega RS, Li C, **Lee GC**. Evaluation of LL-37 antimicrobial peptide derivatives alone and in combination with vancomycin against *S. aureus*. *J Antibiot (Tokyo)*. 2018;71(11):971-4. Epub 2018/08/19. doi: 10.1038/s41429-018-0090-7. PubMed PMID: 30120393.
82. Tun K, Shurko JF, Ryan L, **Lee GC**. Age-based health and economic burden of skin and soft tissue infections in the United States, 2000 and 2012. *PloS one*. 2018;13(11):e0206893. Epub 2018/11/02. doi: 10.1371/journal.pone.0206893. PubMed PMID: 30383858; PMCID: PMC6211756.
83. Argamany JR, **Lee GC**, Duhon BD, Zeidan AR, Young EH, Reveles KR. A possible association between statin use and improved *Clostridioides difficile* infection mortality in veterans. *PloS one*. 2019;14(5):e0217423. Epub 2019/05/29. doi: 10.1371/journal.pone.0217423. PubMed PMID: 31136602; PMCID: PMC6538245.
84. Le S, **Lee GC**. Emerging Trends in Metformin Prescribing in the United States from 2000 to 2015. *Clin Drug Investig*. 2019;39(8):757-63. Epub 2019/05/28. doi: 10.1007/s40261-019-00799-0. PubMed PMID: 31124014.
85. Liu K, **Lee GC**. Healthcare utilization and cost expenditures for pneumonia in individuals with diabetes mellitus in the USA. *Epidemiology and infection*. 2019;147:e212. Epub 2019/08/01. doi: 10.1017/s0950268819000979. PubMed PMID: 31364575; PMCID: PMC6624864.
86. So W, Shurko J, Galega R, Quilitz R, Greene JN, **Lee GC**. Mechanisms of high-level ceftolozane/tazobactam resistance in *Pseudomonas aeruginosa* from a severely neutropenic patient and treatment success from synergy with tobramycin. *J Antimicrob Chemother*. 2019;74(1):269-71. Epub 2018/10/09. doi: 10.1093/jac/dky393. PubMed PMID: 30295837.

### Rozmin Jiwani, PhD, RN

#### Phase 1 Publications (1/19 to present)

87. Espinoza SE, **Jiwani R**, Wang J, Wang CP. Review of Interventions for the Frailty Syndrome and the Role of Metformin as a Potential Pharmacologic Agent for Frailty Prevention. *Clinical therapeutics*. 2019;41(3):376-86. Epub 2019/03/11. doi: 10.1016/j.clinthera.2019.01.006. PubMed PMID: 30851950.
88. Espinoza SE, Musi N, Wang CP, Michalek J, Orsak B, Romo T, Powers B, Conde A, Moris M, Bair-Kelps D, Li Y, Ganapathy V, Jergensen TE, Kelly LC, **Jiwani R**. Rationale and Study Design of a Randomized Clinical Trial of Metformin to Prevent Frailty in Older Adults with Pre-Diabetes. *The journals of gerontology Series A, Biological sciences and medical sciences*. 2019. Epub 2019/03/20. doi: 10.1093/gerona/glz078. PubMed PMID: 30888034.

## **Jia Nie, PhD**

### **Phase 1 Publications (1/18 to present)**

89. Zhang X, Zhang J, Sun H, Liu X, Zheng Y, Xu D, Wang J, Jia D, Han X, Liu F, **Nie J**, Shi Y. Defective Phosphatidylglycerol Remodeling Causes Hepatopathy, Linking Mitochondrial Dysfunction to Hepatosteatosis. *Cell Mol Gastroenterol Hepatol*. 2019;7(4):763-81. Epub 2019/03/05. doi: 10.1016/j.jcmgh.2019.02.002. PubMed PMID: 30831319; PMCID: PMC6463126.
90. Song C, Zhang J, Qi S, Liu Z, Zhang X, Zheng Y, Andersen JP, Zhang W, Strong R, Martinez PA, Musi N, **Nie J**, Shi Y. Cardiolipin remodeling by ALCAT1 links mitochondrial dysfunction to Parkinson's diseases. *Aging Cell*. 2019;18(3):e12941. Epub 2019/03/07. doi: 10.1111/ace1.12941. PubMed PMID: 30838774; PMCID: PMC6516155.
91. Liang H, **Nie J**, Van Skike CE, Valentine JM, Orr ME. Mammalian Target of Rapamycin at the Crossroad Between Alzheimer's Disease and Diabetes. *Advances in experimental medicine and biology*. 2019;1128:185-225. Epub 2019/05/08. doi: 10.1007/978-981-13-3540-2\_10. PubMed PMID: 31062331.

## **Robyn Scherber, MD, MPH**

### **Phase 1 Publications (6/19 to present)**

92. Surapaneni P, **Scherber RM**. Integrative Approaches to Managing Myeloproliferative Neoplasms: the Role of Nutrition, Exercise, and Psychological Interventions. *Curr Hematol Malig Rep*. 2019;14(3):164-70. Epub 2019/05/17. doi: 10.1007/s11899-019-00516-w. PubMed PMID: 31093888.
93. Palmer J, Kosiorek HE, Wolschke C, Fauble VDS, Butterfield R, 3rd, Geyer H, **Scherber RM**, Dueck AC, Gathany A, Mesa RA, Kroger N. Assessment of Quality of Life following Allogeneic Stem Cell Transplant for Myelofibrosis. *Biol Blood Marrow Transplant*. 2019. Epub 2019/07/10. doi: 10.1016/j.bbmt.2019.07.001. PubMed PMID: 31288096.
94. **Scherber RM**, Mesa RA. Management of Challenging Myelofibrosis after JAK Inhibitor Failure and/or Progression *Blood Rev*. Accepted.

## **Mitzi Gonzales, PhD, Clinical Neuropsychology**

### **Phase 1 Publications (6/19 to present)**

95. Morin RT, **Gonzales MM**, Bickford D, Catalinotto D, Nelson C, Mackin RS. Impaired Financial Capacity in Late-Life Depression: Revisiting Associations with Cognitive Functioning. *Journal of the International Neuropsychological Society: JINS*. 2019:1-6. Epub 2019/08/07. doi: 10.1017/s1355617719000705. PubMed PMID: 31383048.